The primary purpose of this study is to investigate the safety and tolerability of AZD0328 following once-daily dosing for 13 days in elderly healthy volunteers and to define maximum tolerated dose.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
112
Research Site
Linköping, Sweden
Research Site
Luleå, Sweden
Research Site
Stockholm, Sweden
Research Site
Uppsala, Sweden
Safety and tolerability of AZD0328 by assessment of vital signs, laboratory variables and ECG
Time frame: Assessments taken at visit 1 (enrolment), during visit 2 (residential period) and follow up visit 3.
Safety and tolerability of AZD0328 by assessment of adverse events
Time frame: Non serious adverse events will be collected from the start of residential period until the end of the study. Serious adverse events will be collected from signing of consent until end of study.
Determine the single and multiple dose pharmacokinetics (PK) of AZD0328
Time frame: PK sampling taken at defined timepoints during residential period.
Evaluate the cognitive dose response relationship for AZD0328
Time frame: Psychometric test battery performed at defined timepoints during residential period.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.